MannKind may be on the precipice of growth surge thanks to Afrezza, but these three biotech stocks are still growing faster than MannKind.
These 10 stocks were the top large-cap performers in healthcare during 2014.
There's more to top dividend-paying stocks than the yield.
Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?
Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.
Just because you own Allergan doesn't mean you should necessarily own Actavis.
Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.
Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.
Alnylam's third-quarter earnings call was all about the pipeline data.
Actavis posted third-quarter earnings this morning. Here's what you need to know.